Grifols (OZTA) AI Stock Analysis

Grifols

(BX Swiss:OZTA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Integrated plasma platformVertical integration gives Grifols control across plasma collection, manufacturing, and distribution. This can support supply security, production coordination, and scale economies, strengthening the company’s ability to serve hospitals and healthcare providers over multiple quarters.

Negative Factors

Elevated leveragePersistently high debt relative to equity limits financial flexibility and leaves less room for operational setbacks or large strategic investments. Leverage also increases the importance of sustained cash generation, making balance-sheet improvement a continuing business priority.

Grifols (OZTA) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 6.01B
Dividend Yield: 1.87%
Average Volume (3M): 1,000
Price to Earnings (P/E): 16.4
Beta (1Y): 0.66
Revenue Growth: -0.33%
EPS Growth: 51.93%
Country: Switzerland
Employees: 25,258
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - General

Grifols Business Overview & Revenue Model

Company Description

Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from pl...

Grifols Risk Analysis

Grifols disclosed 53 risk factors in its most recent earnings report. Grifols reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Failure to comply with changing regulatory requirements could materially adversely affect our business.Q4, 2020

2.We rely on the services of third parties for the manufacture of certain products.Q4, 2020

3.Our business could suffer as a result of the United Kingdom's decision to end its membership in the European Union.Q4, 2020

Grifols Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

CH:OZTA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ES:ROVI	78Outperform	EUR 3.16B	17.28	27.84%	1.53%	3.21%	39.34%
ES:ALM	65Neutral	EUR 2.31B	32.00	4.78%	1.74%	9.67%	174.00%
ES:FAE	61Neutral	EUR 1.50B	11.10	18.19%	2.65%	31.88%	-20.09%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ES:RJF	52Neutral	EUR 212.43M	30.46	3.14%	0.75%	-0.42%	4.56%

* General Sector Average

Performance Comparison

CH:OZTA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:OZTA	Grifols (0RDU)	10.05	0.54	5.64%
ES:ALM	Almirall SA	10.60	-1.34	-11.24%
ES:FAE	Faes Farma	4.83	0.50	11.59%
ES:RJF	LABORATORIO REIG JOFRE	2.58	-0.29	-10.01%
ES:ROVI	Laboratorios Farmaceuticos Rovi	62.55	3.88	6.61%
ES:IKM	1nKemia IUCT Group SA	0.31	0.00	0.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Grifols AI Stock Analysis